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Abstract

Molecular biology techniques and low cost reagents have lowered the
barriers to entry for development of biological arsenals by non-state and state
groups. Additionally, genetic engineering of epitope targets from such pathogens
as Y. pestis would annul current detection methods and therapeutic treatments.
Vaccines often have short shelf lives and are of minimal utility if not used prior to
exposure to BW agents.

Camelidae, including camels and llamas produce

unique antibodies termed Nanobodies® (Nbs) or antigen specific fragments (VHH)
which are much smaller than traditional antibodies (15 vs. ~150 kDal) yet seem
to attach with the same selectivity and affinity as full antibodies. VHH are more
stable than the fragile, more bulky antibodies and maintain their structure and
function even at high temperature and humidity. It is thought that, due to these
unique characteristics, VHH could be reconstituted from a lyophilized pellet and
used as a real time injectable immunotherapeutic to be used when warfighters
have been exposed to BW. Two logical candidates for VHH production are the
low-calcium-response V protein (LcrV) and the needle-like Yop (Yersinia Outermembrane Protein) Secretion Protein F (YscF).

This effort successfully

produced quantities greater than 1-mg purified native recombinant LcrV and
YscF proteins as antigens for VHH production.
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PRODUCTION OF RECOMBINANT INJECTOSOME AND OUTER MEMBRANE
PROTEINS FROM YERSINIA PESTIS KIM5

1. Introduction
1.1 Chapter Overview
Yersinia pestis, formerly Pasteurella pestis, has long been a blight upon
the human species.

As the causative agent of bubonic, septicemic, and

pneumonic plagues, this bacterium has caused the deaths of hundreds of
millions of people. Due to its high mortality rate, potential for major public health
impact, potential to cause public panic and social disruption, and special actions
required by public health, the Centers for Disease Control has classified Y. pestis
as a Category A Agent (CDC 2009). This bacterial disease is endemic in a large
portion of the globe including the continental United States, South America,
Southeast Asia and parts of Africa (WHO 1970).

While transmission of this

zoonotic disease is often through flea bites, indigenous populations of rats, mice,
and other members of the order rodentia harbor the bacteria. Aerosolized carrier
byproducts or direct contact with an infected organism may also result in illness.
The human infection type (bubonic, septicemic, and pneumonic) of Y. pestis may
start in one or more systems in the body depending upon route of entry. The
WHO reports there are 1000-2000 naturally occurring reported cases each year
(WHO 2009). If untreated with antibiotics the fatality rate ranges from 50-60% for
bubonic plague to nearly 100% for septicemic and pneumonic plague. Taken
1

together, 1 in 7 cases are fatal among treated and untreated victims in the United
States (WHO 2009).
1.2 Problem Statement
The barrier to entry in the fields of microbiology and molecular biology has
never been lower. Literature is publically and easily available for culturing many
hazardous agents, and several massive public electronic databases exist with
the sequences of Marburg Virus, Variola Virus, and others.

The medical

community has several tools to combat these biological threats; however, genetic
manipulation of critical genes and the long lag time for vaccine development may
limit their effectiveness against purposeful targeted BW outbreaks.
1.3 Proposed Solution
One tool that may combat this threat is the use of immunotherapeutic
administration of antigen specific fragments (VHH). VHH are produced by cleaving
a variable, antigen-specific domain from naturally occurring single-domain
Camelid antibodies.
The present study will overproduce and purify two Yersinia pestis KIM5
(Appendix C. Strains) proteins, LcrV and YscF, using molecular biology
techniques, to be used as antigens for VHH development.

The DNA gene

sequences coding for these proteins will be put into expression vectors and
transformed into E. coli. The protein over-expression and purification will be
performed without the aid of fused N- or C-terminal tags.
1.4 Research Questions
1. Can LcrV and YscF be over-expressed in E. coli and purified without
tags?
2

2. Is the protein able to be over-expressed to a significant degree for
purification?
3. Does the E. coli modify the proteins’ primary structure posttranslationally?
1.5 Significance of Results
The study of VHH as immunotherapeutics for combating the deleterious
effects from biological weapons of mass destruction is a credible and working
pursuit for the DoD, as evident by their funding of immunotherapeutic research.
Producing and purifying these two recombinant proteins is the initial step for
production of the VHH. In April 2009, 2 mg quantities of purified recombinant LcrV
and YscF was shipped to Air Force Research Laboratory collaborators in
Belgium for VHH development. The efficacy of the VHH to protect against Y. pestis
infection will determine their future for in vivo DoD applications.
1.6 Research Focus
The methods and tools that will be applied answering the research
questions are:
1. Clone genes for LcrV and YscF DNA and sequence verity constructs
2. Transfer genes into expression vectors
3. Transform constructs into expression strains and express the proteins.
4. Harvest and purify excess of 2 mg of both LcrV and YscF proteins.
1.7 Methodology
1.7.1 Plasmid Development
Genomic DNA extracted from Y. pestis KIM5 was used as a PCR template
to clone gene sequences. Custom primers flanking the entire 5’ to 3’ region of
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DNA coding for native LcrV and YscF proteins were employed to replicate the
sequences.

Amplification was followed by an initial round of ligation and

transformation into pCR2.1 and TOP10F’ (Appendix C. Strains). This construct
was DNA sequence verified before restriction digest removal of the gene and the
second round of ligation into pET24a+ and transformation into strain DH5α
(Appendix C. Strains). Constructs were again sequence verified and pET24a+LcrV and pET24a+-YscF were finally transformed into the E. coli expression
strain BL21(DE3) (Appendix C. Strains).
1.7.2 Protein Expression
The LcrV and YscF constructs in the expression strain were initially tested
for protein induction in small 3 mL volumes. The induced whole cell pellet was
lysed and analyzed by SDS-PAGE. A very large induced band was observed at
approximately the predicted MW of 10 and 32 kDal for YscF and LcrV,
respectively.

The LcrV protein production was successfully upscaled to 2 L

without further modification; however, YscF production required multiple, smaller
quantities in baffled flasks. After induction with IPTG, the cells were harvested,
and resuspended for lysis via French Press.

The lysed cell homogenates were

centrifuged and the resultant pellet saved for further protein purification.
1.7.3 Protein Purification
The cell homogenates were further purified by ammonium sulfate
precipitation.

This step successively precipitates the suspended cellular

constituents according to their solubility in increasing salt conditions.

The

fractions that contained the highest relative quantity of LcrV or YscF were used in
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further purification steps. FPLC was the primary instrument for purification [GE
AKTAexplorer™ system] utilizing HIC affinity, size exclusion, and anion
exchange columns. LcrV and YscF had different purification schemes; however
both yielded native protein in purities of about 99%.
1.8 Assumptions
Two assumptions were made when designing the experimental
architecture for this research.
1. E. coli tertiary structure folding will be similar as in Y. pestis in that
post-translational modifications and self-grouping (dimers, trimers, etc.)
are the same in Y. pestis KIM5 and CO92 and E. coli BL21(DE3).
2. Purification in the manner described below will not significantly alter
the structure, thus antigenic properties and epitope locations in the two
proteins.
With respect to assumption 1, the primary structures of LcrV and YscF
were sequenced and found 99% and 98% homologous to the NCBI published
predicted sequences. The 1% and 2% difference is due to the post translational
modification in which the methionine is cleaved from the N-terminus of both
proteins.

This irreversible cleavage is catalyzed by the enzyme methionine

aminopeptidase (MAP) in E. coli. Y. pestis also has MAP and most likely also
cleaves off this residue.
It has been assumed that due to the self-folding of most prokaryotic
proteins in vivo, LcrV and YscF should be able to refold after being denatured.
YscF in low salt (NaCl) conditions and high salt conditions rapidly precipitated out
of solution, indicating that it is polymerizing as previously shown (Hoiczyk 2001).

5

1.9 Implications
This research completes the initial step by preparing the two recombinant
proteins for VHH production.

By using native proteins as antigens, the VHH

produced may have a higher probability to recognize previously unknown
epitopes found in protein clefts currently inaccessible by the much larger
antibody molecule. Once the VHH are produced and characterized, several in
vitro Y. pestis neutralization and protein binding assays will quantitatively
measure VHH affinities. In addition, efficacy of VHH protection will be examined by
use of human primary macrophage model and an in vivo murine model.
1.10 Document Overview
This paper begins in Chapter 2 with the current threat assessment for
WMD and leads to an understanding of the potential therapeutic uses of VHH and
the antigen choices. Chapter 3 describes the over-production of LcrV and YscF
proteins, the first step to VHH production. The results of the production are in
Chapter 4 and conclusions in Chapter 5.

6

2. Literature Review
2.1 Background
This chapter lays out an argument for the DoD and other National Security
Organizations to investigate the potential of VHH as immunotherapeutics and the
rationale and methods behind such an endeavor. This chapter also discusses
the threat of biological agents past and present, the mechanisms of invasion and
infection causing morbidity and mortality by many parasitic bacteria, and the use
of biologically developed antibodies for combating disease.
2.2 Threat Assessment from WMD
2.2.1 Overview
Due to the heinous potential of biological weapons’ effects on the human
population, both direct (human morbidity and mortality) and indirect (economic,
psychological, etc.), policy makers of the last century have made several global
efforts to curtail the development, production, stockpiling, and acquisition of
these agents (Inglesby 2000, Radosavljevic 2007).

Policy creation or change

has been in response to an exceptional event or events civilization deems
morally reprehensible. The Geneva Protocol was the first modern (within last
century) attempt to curb the use of biological weapons (Geneva 1925). This
treaty opened for signature on June 17, 1925 and entered into force on February
8, 1928. The signatories called for the prohibition of both chemical and biological
weapons, in response to the militaries’ judicious use of chemical and, to lesser
extent, biological weapons during WWI. The protocol stated that the use of such
weapons “has been justly condemned by the general opinion of the civilized

7

world…” Much of the treaty was ignored and did little to prevent the subsequent
biological arms race ensuing multilaterally between the US, the USSR, the UK,
Japan, and several other states from the 1930s to the 1970s (Department of the
Army 1997, Parlement of the United Kingdom 1974).
President Richard M. Nixon, on November 25, 1969, guided by his
Secretary of Defense, Melvin Laird, and the National Security Council, issued the
Statement on Chemical and Biological Defense Policies and Programs
dramatically changing US policy on biological weaponry.

This statement

summarized 1) the US no-first strike policy with regards to chemical weapons; 2)
the renouncement of use of lethal biological agents and weapons, and; 3) the
continuance of very limited biological weapons research for defensive purposes.
His political decision was motivated by the high cost of the US biological weapon
program, low public opinion of the military during the Vietnam War era, and the
strategic weapon redundancy due to our growing nuclear arsenal (Nixon 1969).
Nixon’s

pronouncement

brought

about

the

Biological

Weapons

Convention, a multilateral treaty, which, if completely enacted, would eliminate
the development, stockpiling, and transferring of this entire class of weapons
amongst the signatories. The treaty entered into force on March 26, 1975, and
currently has 162 signatories who agree to disallow development, production,
stockpiling, and transfer of biological weapons (CWTC 1972). Israel remains a
non-member along with several other countries most of which are in continental
Africa (United Nations 2009).

Current BW threats vary in scope, scale, and

target. They may range from large, highly funded state-sponsored bioweapons
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programs to single-operatives. The latest threats have been towards the singleoperative side of the spectrum (BBC-1 2001) (Hosenball 2008) (A Security
Source 2009).
2.2.2 State Players (Since 1970s)
Despite being signatories of the 1972 Biological and Toxin Weapons
Convention (BWTC) several states continued research in biological weaponry.
The former Soviet Union was an early participant in biological weapon
experimentation and believed the US’ stance, voiced by Nixon, was a ploy to
disarm all but itself of biological weapons (Alibek 1999). Between 1973 and
1974, as the US was disarming itself, the Soviet government developed a new
organization, under the guise of civilian biotechnology research, named
Biopreparat, to develop a host of cutting edge biological weapons.

Several

publically acknowledged incidences in the last 30 years indicate a robust, highly
funded Soviet biological weapon machine (Alibek 1999, Davis 2006).
Georgi Markov, a Bulgarian critic of the Communist government, was
assassinated in London on September 7, 1978, by use of a ricin-coated pellet.
While ricin, a protein toxin found in the seeds of the castor bean plant, is not an
infectious or living pathogen, its use is banned by the BWC of 1972. Recent
evidence supports the argument that the assassination was made by the
Bulgarian secret service aided by the Soviet KGB (The Economist 2009).
Another instance of an active Soviet post-BWTC development program
was the accidental release of anthrax spores in April 1979 upon the town of
Sverdlovsk (now Yekaterinburg, Russia).
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Sensationally called “the biological

Chernobyl,” the accidental microbial release from a BW research facility caused
the death of approximately 100 people (Meselson 1994, Alibek 1999).
As shown in the case of the former Soviet Union, signing the 1972
Biological Weapons Convention did not eliminate the aspiration, capability, or
actions of a country to pursue the weaponization of biological organisms. Iraq
signed the BWTC on 11 May 1972, but was not ratified until 1991. The Iraqi
government, led by the former president Saddam Hussein, developed chemical
and biological weapons programs in the mid 1980s to combat the Iranians during
the Iran-Iraq war from 1980-1988 (Cordesman 1998). The strains investigated
include Bacillus anthracis, Yersinia pestis, Clostridium botulinum and perfringens,
species of afatoxin-producing fungi, and several others (Smith 1997). Acquisition
of these strains, obtained through routing the orders to the American Type
Culture Collection (ATCC) via the University of Baghdad, was met with very little
opposition, as very little was required to prove the legitimacy and intent of such
purchases. In a similar fashion, Libya signed the Geneva Protocol in 1925 and
the BWTC in 1982 and developed limited biological weapon capabilities but failed
to establish a significant program due to a lack of indigenous scientific and
engineering infrastructure (NTI 2009). These three cases serve as examples of
state/military funded biological weapons programs that were conducted in spite
of the BWTC.
2.2.3 Non-state Players
While the quantities produced by large state funded research and
development centers are orders of magnitude larger than can be produced by an
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individual or small group, the most recent attacks have been from non-state
sponsored

organizations.

Three

intriguing cases

are

the

Salmonella

contaminated salad bar, the 2001 anthrax letters, and the recent mysterious
deaths of forty Al-Qaeda terrorists in Algeria.

These

examples

demonstrate

the potential for small players to impact large populations.
As the only successful culture and release of a pathogen, the Rajneeshee
cult, led by Bhagwan Shree Rajneesh, contaminated several restaurants with
Salmonella enterica Typhimurium (Leitenberg 2005). The attack at The Dalles,
Oregon, in 1984, sickened over 750 people, 45 of which were hospitalized
(Grossman 2001).

The event was the prototypical domestic terrorist event

demonstrating the fragility and severe limitation of the public health community
who protect such a large range of targets.
Another widely publicized terrorist/BW act was the 2001 anthrax letters,
which targeted two US Senators and several media companies. The biological
material contained in the letters, which caused five deaths and the infection of 17
others, was composed of dry Bacillus anthracis spores.

While the media

speculated wildly as to the grade of the spores, several subject matter experts
found no evidence of significant weaponization (Alibeck 2002). The likely culprit
was US scientist, Bruce Edward Ivins, Fort Detrick, Md, who had access to the
strain (Hosenball 2008).
The third case demonstrates the interest groups, such as al Qaeda, have
acquiring CBW.

Several newspapers have recently reported the accidental

deaths of at least forty al Qaeda operatives. Initial reports from several UK
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newspapers claimed the death may be attributed to the biological agent Yersinia
pestis, while US newspapers have been much more conservative with their
estimates and say the agent may be chemical or biological (Lake 2009, A
Security Source 2009, The Daily Telegraph 2009). The three cases have and
will continue to shape policy and funding regarding biological weapons.
2.3 Bacterial Based Biological Weapons (BBBW)
As with chemical or nuclear weapons, biological weapons require special
materials to deliver an effective attack (9/11 Commission 2004). These special
biological materials or “barriers to entry” can be easily acquired, when compared
to nuclear and chemical weapons. This is in part due to dual use equipment,
ease of culture methods, and easily available pathogen sequences published in
articles and posted on the internet. The Australia Group (AG) is a cohort of over
forty countries who meet annually to promote national export licensing which:
1. are effective in impeding the production of chemical and biological
weapons;
2. are practical, and reasonably easy to implement; and
3. do not impede normal trade materials and equipment used for
legitimate purposes (Australia Group 2008).
The domestic regulation of bacterial based biological weapons is difficulty
due to dual-use of the processing vessels and equipment in legitimate public
health, academia, commercial R&D, and medical establishments.

Dual-use

equipment, common at even small undergraduate research facilities and local
public heath offices, include fermenters, autoclaves, centrifuges, and incubators
(Shea 2004).

These rudimentary culture devices are easily attained through
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relatively anonymous sources such as ebay.com.

Bacterial-based biological

weapons are much easier to produce than spore-forming agents or viruses since
they require less downstream handling.
The CDC classifies biological agents/diseases into three groups, based
upon a metric which considers transmission, mortality rates, public perception,
and public health resources (CDC 2009). Of the six Category A Agent/disease
groups (Table 1) only two fall into the classification of BBBW, these include
Francisella tularensis (the causative agent of Tularemia) and Yersinia pestis.
Both these organisms are regularly transmitted by arthropod vectors and are
naturally endemic in North America and other parts of the world. Both pathogens
are harbored in small mammals as reservoir hosts (Morner 1992). As evident by
centuries of morbidity and mortality, Y. pestis is transmissible from one human to
another, making it unique among bacterial Category A Agents.
Table 1. CDC Category A Agents

Agents
Bacillus anthracis
Clostridium botulinum toxin
Yersinia pestis
variola major
Francisella tularensis
filoviruses and arenaviruses

Classification
Spore, Bacterial
Toxin, Bacterial
Bacterial
Viral
Bacterial
Viral

Spread Human-to Human
No
No
Yes
Yes
No
Yes

2.4 Yersinia pestis
2.4.1 Overview
With the exception of smallpox (with no known animal reservoir), and C.
botulinum (a toxin producer found in food), all of the Category A Agents are
zoonotic diseases, as they are shared by animals and humans (CDC 2009).
13

Arguably, the genus Yersinia has impacted human kind more than any other
pathogen due to its widespread and lasting effects.

The causative agent of

plague has been implicated in the death of over 200 million people in three
pandemic waves in the last 1500 years. It was not until 1894, while investigating
the Manchurian Pneumonic Plague epidemic in Hong Kong that bacteriologist
Alexandre Emile Jean Yersin discovered the gram-negative bacillus causing the
plague, satisfying Koch’s Postulates.
2.4.2 Historical and Modern Classification Models
The study of relationships between living organisms is very important
within the field of pathology. Edward Jenner’s research and observations in the
late 1700s, while pre-dating comparative genetics, uncovered the phenotypic and
antigenic similarities between Vaccinia virus (the agent of cowpox) and Variola
major (the agent of smallpox).
The genus Yersinia of the family Enterobacteriaceae contains over a
dozen species including three which cause disease in humans (Table 2).
Table 2. Yersina Species and Diseases

Species
Y. enterocolitica
Y. pseudotuberculosis
Y. pestis

Disease
Yersiniosis
Izumi-fever, gastroenteritis
Plague

Y. pestis is hypothesized to have evolved from Y. pseudotuberculosis
within the last 1,500 to 20,000 years (Achtman 1999).

The large range in

postulated dates is due to the large reproductive rates and extreme selection
shown by pathogens. The level of divergence between species depends upon
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the strain and can be quantified using several different methods. Figure 1 shows
the quantification of gene loss of function/inactivation in Y. pestis is compared to
Y. pseudotuberculosis.

The darker columns represent a relative loss of

analogous gene clusters for Y. pestis strain CO92 and light blue (lighter)
represent relative loss for Y. pseudotuberculosis strain IP32953 (Chain 2004).
Notably, large scale gene inactivation of Y. pestis may be the cause of its
increased pathogenicity (Chain 2004).

Figure 1. Active Y. pestis gene groups compared to Y. pseudotuberculosis
(Chain 2004)
Image used with permission of PNAS (copyright 2004 National Academy of Sciences, U.S.A) and
Author

The historical (classical) subspecies classification subdivided Y. pestis
strains into one of three biovars: antiqua, mediaevalis, and orientalis (closely
related to Justinian’s plague and the Black Death). Recently, microtus has been
proposed as a possible fourth subspecies (Zhou 2004). These divisions were
phenotypically differentiated using the strains’ glycerol fermentation and nitrate
15

reduction abilities and geographic location. These phenotypic variations have
been assumed to represent/model significant changes within the strain’s genome
and mark evolutionary divergences. Recent advances, chiefly the increased
fidelity and affordability of sequence and mutation analysis (single nucleotide
polymorphisms, variable number tandem repeats, and insertion deletions), have
allowed researchers to challenge and build upon existing nomenclature
paradigms (Touchman 2007). Proposed changes include addition of new biovars
to complete reclassification based upon molecular signatures (Zhou 2004,
Achtman 2004).

The three classic biovars range in levels of morbidity and

mortality ranging from the highly virulent CO92 (pronounced Colorado 92) to the
avirulent KIM5 strain that can be handled at BSL2.
2.4.3 Forms of Infection
Another key factor in Y. pestis lethality is the form of infection within the
host. The three common forms of infection include bubonic, septicemic, and
pneumonic.

Each has a different manifestation and mortality rate; however,

patients are not limited to one form.

The commonly referenced form is the

bubonic plague. Within a less than a week of open skin contact to Y. pestis or a
bite from an infected flea, symptoms of fever, headache, chills, and inflammation
of the lymph nodes develop.
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Figure 2. Xenopsylla chepsis (oriental rat flee) engorged with blood (CDC 2009)

Figure 3. Inguinal Bubo (CDC 2009)

While this form is not always fatal, it often leads to the second more lethal
form, septicemic plague.

Septicemic diagnosis is given when an individual’s

blood has positive culture for the bacteria (Perry 1997).

It has been reported

that blood cultures range from 10 to 4 x 107 colonies/mL; patients with colony
counts higher than 100/mL have higher fatality rates; however, survival with
counts as high as 107/mL has been reported (Butler 1976).
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Figure 4. Plague Bacteria in Blood (CDC 2009)

The third form, pneumonic plague, is transmitted when infectious droplets
are successfully deposited deep within the respiratory system. In 1994 it was
reported that only 12% of U.S. patients diagnosed with pneumonic plague
developed it from primary bubonic or septicemic infections (Doll 1994). It should
be noted that vaccines, whose efficacy has never been precisely calculated,
reduce the incidence and morbidity of the disease in individuals bitten by infected
fleas. A vaccine using attenuated live plague has been discontinued as it is still
pathogenic and yields low protection from respiratory exposure (Titball 2001).
2.4.4 Human and Zoonotic Lifecycles
As previously mentioned, there are several routes of exposure to plague.
The exposure methods to humans are:
1. Direct contact with infected wild or domestic animals (usually rodents)
2. Bite from infected flea
3. Person to person via infected bodily fluids (pneumonia plague)
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Figure 5. Plague Lifecycles
Adapted from Neal Chamberlain’s Medical Microbiology: The Big Picture

All three of these routes of entry could be employed by a terrorist to infect
an individual or population.
2.4.5 Genetic Components of Infectivity
In the same year (2001) the human genome was first published,
researchers from the Wellcome Trust Sanger Centre released the sequence of Y.
pestis CO92 (Parkhill 2001). CO92, the prototypal strain, has a genome of one
chromosome with 4.65 x 106 base pair (bp) and three relatively smaller plasmids
(circular DNA).
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Figure 6. Y. pestis CO92 Genetic Features (to scale)
(Parkhill 2001)

The bacterium’s chromosome encodes primarily the housekeeping genes
but also includes several virulence factors (CEVF). CEVF are necessary for full
virulence in the case of the Y. pestis model Y. enterocolitica (Heesemann 1984).
While CEVF play a lesser role in pathogenicity, pCD1 the 70 kbp virulence
plasmid, codes for many of the proteins primarily responsible for infection. The
70 kbp plasmid (pCD1 in pestis, pYVe in enterocolitica, and pYV or pIB1 in
pseudotuberculosis) is common to all three pathogenic species within Yersinia.
Two specific proteins of interest are coded in this plasmid: the low calcium
response V protein (LcrV) and yop (Yersinia outer-membrane protein) secretion
protein F (YscF). These two proteins, which are necessary for virulence, have
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been used as target antigens for antibody production (Burrows 1956, Cornelis
1997).
2.5 LcrV and YscF Proteins
2.5.1 LcrV
The low calcium response V or V-antigen was the first virulence
determining factors of Yersinia pestis (Burrows 1956).

Among the Yersinia

species, the LcrV coding sequence demonstrates a 90-95% homology (Weeks
2002).

Figure 7. LcrV Amino Acid Comparison amongst Yersinia and Similar Species

Figure 8. Structure of Y. pestis LcrV
(Overheim 2005)
Image used with permission of American Society for Microbiology (license number
2170320732934) and Author
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The high level of homology is supportive evidence of the importance of
this factor for the survival and infectivity of this species. The pCD1 (pYV) vector
contains a 981 bp gene that codes for the 327 amino acid LcrV sequence. The
role that LcrV plays has been somewhat illusive, most likely due to its multiple
roles in pathogenicity. It has been shown that LcrV stimulates host expression of
interleukin 10 (IL-10), suppressing the host’s innate immune system (Nakajma
1995). Several other roles have been observed in animal models, many of which
also involve suppression of the host response to infection.
2.5.2 YscF
Several gram-negative animal and plant pathogenic bacteria share a
similar secretion mechanism for translocating proteins into a host’s cytoplasm.
These proteins, while species specific, are activated by contact with cell surface
moieties and lead to suppression of host immune responses (Hueck 1998).
Yesinia species, Salmonella typherim, Shigella flexneri, and enteropathogenic E.
coli all share this type three secretion system (T3SS or TTSS). A key player in
the T3SS is a small surface expressed protein named YscF. YscF also shares a
high level of homology amongst Yersinia species as demonstrated in Figure 9.

Figure 9. YscF Amino Acid Comparison amongst Yersinia and Similar Species
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Figure 10. YscF Images
(A) in vivo cross section analysis of needles of Y. enterocolitica; (B) Isolated needles; (C)
Aggregated upon Ca+2 addition (bars are 50 nm) (Hoiczyk 2001)
Image used with permission of PNAS (copyright 2001 National Academy of Sciences, U.S.A) and
Author

The pCD1 (pYV) vector also contains the 264 bp coding for the 88 amino
acid sequence of YscF weighing 7 kDal.

This small protein is a monomer

creating relatively large hollow needle-like polymers.

YscF has also been

demonstrated to serve as protective antigen as it issues a robust immune
response (Swietnicki 2005). This needle (injectosome) provides the channel for
the Yops to move from Yersinia into the host cell as depicted in Figure 10.
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Figure 11. YscF Injectosome Penetrating Host Cell

As both LcrV and YscF are located on the exterior of Yersinia’s outer
membrane and are necessary for pathogenicity, they are ideal candidates for
antibody production to target Y. pestis.
2.6 Antibodies and Antigen Specific Camelidae Fragments
2.6.1 Overview
Antibodies or immunoglobulins (Ig) are proteins produced by living
organisms in response to the presence of an antigen.

The innate immune

systems of vertebrates quickly and non-specifically respond to foreign objects
with increased circulation, elevation of temperature, and recruitment of cellular
and non-cellular helpers. However, the adaptive immune system develops a
targeted, more lethal attack. Previously produced antibodies are constitutively
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expressed to some degree after exposure, providing a faster response to future
attacks.
2.6.2 Structure of Antibodies
Antibody responses exist in all vertebrates.

The most common

immunoglobulin species (up to 75% of immunoglobulins in human serum) is
immunoglobulin G (IgG). This Y-shaped molecule is structurally composed of
two heavy chains and two light chains. The heavy chain can be broken down
further to smaller domains consisting of a variable region (VH) and a larger
constant region (CH).

Similarly, the light chain can be broken into a small

variable region (VL) and only slightly larger constant region (CL). As displayed in
Figure 12 the four regions come together to form the quaternary structure of the
protein.

Figure 12. Immunoglobulin G Structure
*denotes variable region conferring variability and specificity
(Ribbon Structure from Wikipedia)
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2.6.3 In vivo and in vitro Antibody Production
Predating the discovery of antibodies in the late 19th century, scientist
recognized the ability for the human body to respond to a pathogen and acquire
immunity to future exposures. Edward Jenner’s model of using a surrogate, or
later attenuated and killed pathogens, demonstrated the body’s ability to
generate antibodies without exposure to full virulent pathogens. The polyclonal
antibodies produced in response to the pathogen have affinities for many areas
of the antigen, called epitopes. This antibody fraction or titer can be isolated and
purified from whole blood.
Often pathogens possess surface proteins or features that are very
antigenic, that is, they stimulate strong antibody producing activity by the
adaptive immune system. To produce such antigen-specific IgG’s researchers
can isolate these antigenic proteins from the pathogen in vivo or, by gene
cloning, make recombinant proteins in cell culture. These purified proteins can
be directly injected into an organism with an immune system and the resultant
polyclonal antibodies may be harvested, purified, and used.

In addition, an

outstanding IgG may be followed up with monoclonal antibody production which
allows for perpetual in vivo production. Additionally, while polyclonal antibodies
target many different epitopes, monoclonal antibodies are produced as a single
IgG species and target a single epitope. To accomplish this, an in vitro method
was developed in the 1970s to combine functional B-cells from an exposed
organism’s spleen or blood and fuse them with a myeloma cell line that no longer
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is able to secrete antibodies. These hybridomas (hybrid + myeloma) can be
grown with simple cell culture methods to produce monoclonal antibodies.
While the above methods of antibody/vaccine production have been
commonly used for many years, a new technique of vaccine/antibody production
has emerged. Scientists have developed plasmids that, when directly injected
into organisms, express antigenic proteins (Tang 1992). As of early 2005 over
170 DNA vaccine production and related technology patents have been filed
(DNAvaccine.com 2004). While the possibility of converting the production of our
nation’s expensive and delicate vaccines to this new process has potential
benefits, the antibody response is still insufficient for many disease vaccines. In
2006 a firm from the UK described the first positive results for a DNA-based flu
vaccine which has been moved to Stage II clinical trials (Barnes 2006).
2.6.4 Problems with Antibody-based Therapeutics
While, antibodies from most vertebrate species act with the same
mechanism, foreign antibodies are themselves very immunogenic.

With a

properly functioning immune system, humans produce an antibody response in
1-2 weeks after exposure to antibodies produced in a foreign organism (Isaacs
1990). The immunogenicity of antibodies poses two different problems. First,
patients previously treated or exposed to a non-human antibody, perhaps from a
mouse, would be less likely to benefit from further antibody treatments produced
by the mouse. Second, diagnostic tests using antibodies derived from mice,
namely enzyme-linked immunosorbant assays, can produce erroneous results
due to interferences of the human anti-mouse antibodies or HAMA. In 1990
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research found that 2 of 50 surveyed hospital patients produced a positive titer
for human anti-mouse antibodies (Kricka 1990). In an attempt to trick the human
immune system to accepting non-human antibody therapies, researchers have
“humanized” antibodies by various means. Humanized antibodies or chimeric
antibodies can be produced by fusing the non-human derived variable domain
coding DNA with human constant coding DNA (Wu 2005).

This fused DNA

sequence can be used to produce monoclonal antibodies without using humans
as laboratories for antibody production.

Another approach to avoid

immunogenicity of the antibody therapeutic involves antibody truncation,
eliminating the common targets for the human anti-mouse antibody response for
example. Truncated antigen-binding fragments (Fab) include one light chain and
the top half of the heavy chain that included the binding site.

Figure 13. Fab

Besides immunogenicity to therapeutics, other difficulties arise with
storage and stability of therapeutic and diagnostic antibodies. Antibodies tend to
degrade at room temperature; storage at 4°C (typical refrigerator temperature)
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should not exceed two weeks with the optimal temperature of -20°C (abcam
2009). VHH have been found to be show affinities at temperature as high as 90°C
due to their ability to refold after denaturation (Linden 1999).
In 1993 a research group in Belgium published their investigations into the
unique antibody structure produced by camelids, including camels and llamas
(Hamers-Casterman 1993). It was later found that, due to a G to A mutation, the
splice site was destroyed after the CH1 exon. Further mutations likely increased
the hinge exon length by transposon(s) insertion (Nguyen 2000). Due to these
mutations, the Camelidae family naturally produces both fully functional single
chain antibodies (SCAB) and normally structured IgG. Further work with SCAB
demonstrated an ability to further reduce the size and change the physical
properties. The biotech company, Ablynx, has commercialized the truncation of
the variable region and named these molecules “Nanobodies®” also known as
VHH. These small structures (15 kDal) are, relative to full antibodies, more heat
and pH resistant and stimulate a low immunogenic response when injected into
primates (Gibbs 2005, Ablynx 2007). Figure 14 is a representation of the unique
structure of single domain Camelid antibodies when compared with Figure 12.
They also can be produced using lower eukaryotic microorganisms such as yeast
and prokaryotes such as E. coli in quantities of grams per liter (Frenken 1998).
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Figure 14. Single Domain Camelidae Antibodies

2.6.5 Medical and Military Applications
The environment in theater with which the warfighter must endure
presents a unique set of problems in diagnosis and detection of pathogens. The
traditional antibody detection method, Enzyme-Linked ImmunoSorbent Assay
(ELISA), has limitations for field use due to the instability of the antibody in the
wide temperature range found in theater. This new subclass of antibodies, VHH,
may solve several of these durability issues for use as both a sensor capture
element and as a immunotherapeutic. In sensors, such stability is critical for the
ng/mL to pg/mL sensitivities for marker detection and quantification. VHH stability
may enable stockpiling of immunotherapeutics stored at room temperature. This
not only has beneficial applications for remote field hospitals, but for individual
warfighter kits.
The use of antibody based passive immunotherapeutics is well known, but
inherent difficulties have limited their use and approval. Only twenty-five, as of
2007, have been approved since the inception of the first therapeutic monoclonal
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antibody FDA-approved in 1986.

The majority have applications in cancer

treatment and other civilian life-threatening diseases; however, only one,
Palivizumab (Respiratory Syncytial Virus), is designed to help prevent (not treat)
a pathogenic organism. Most of the difficulties in acquiring FDA approval revolve
around the body’s natural immune response.

VHH inherent physical

characteristics may lend themselves to use as on-site, real-time protection postBW attack by blocking the ability of bacteria in the initial infectivity pathway. By
reducing the size of the therapeutic, there is a reduction in the number of
antigenic sites.

As of 2006, multiple injections of VHH have not triggered an

immunogenic response in the mouse model (Coppieters 2006).

Oral

immunotherapy with VHH, engineered for proteolytic stability, prevented diarrhea
caused by the rotavirus (Vaart 2006). For these reasons VHH may serve as a
battlefield-ready, stable immunotherapeutic.
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3. Methodology
3.1 Introduction
To produce VHH in Camelidae (llama), a total of 1 to 2 mgs of purified
protein must be prepared to use as an antigen.

The protein, once purified,

should be >95% pure to lower nonspecific antigenic response due to impurities.
Therefore, an excess of 2 mg of LcrV and YscF protein need to be purified to
accomplish this level.

Overexpression of these proteins in a bacterial host

required a protein expression vector, containing the appropriate gene,
transformed into an E. coli expression strain. The construct, once built, was
verified, induced, and the induced protein purified. Protein productions with Nand C-terminal tags, such as poly-histidine tails, have become popular due to the
ease of purification post-induction. Affinity columns have been developed that
bind the poly-histidine tail, selectively removing the fused protein from cell lysate,
aiding in purification. However, production of the native protein without nonnative protein fusions is advantageous to antibody production, as native proteins
contain the correct secondary and tertiary structures. However, by expressing
proteins without the His tags, production and purification of LcrV and YscF was
much more difficult and time consuming.

By doing so, new and perhaps

unalterable cleft epitopes will be presented for in vivo VHH production.

The

methodology is divided into three parts as is described in the objectives: 1)
construction of LcrV and YscF expression plasmids; 2) expression of native
proteins in E. coli and; 3) purification of these proteins using fast protein liquid
chromatography (FPLC).
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3.2 Assumptions
There are several key assumptions that were made prior to the
experimental process.
1. E. coli 2º and 3º structure folding of the produced proteins will be
similar as in Y. pestis.
2. Purification in the manner describe below will not significantly alter the
structure thus antigenic properties of the two proteins.
3. The LcrV and YscF proteins will not be toxic to the E. coli cell upon
induction.
3.3 Development of LcrV and YscF expression plasmids
The goal of this objective was construction of two E. coli vectors, one an
expression plasmid coding for the native LcrV protein and the other YscF protein.
These steps are graphically represented in Figure 15.
3.3.1 Design NdeI and XhoI primers for both LcrV and YscF coding DNA
from Y. pestis strain KIM5 as a target for PCR amplification.
3.3.2 Develop PCR amplification protocols for creating NdeI/XhoI sites 5’
and 3’, respectively, to the LcrV and YscF coding PCR product from
Y. pestis KIM5 genomic DNA.
3.3.3 Ligate the LcrV and YscF PCR products into pCR2.1 vector
plasmids.
3.3.4 Transform pCR2.1-LcrV and pCR2.1-YscF vectors into the nonexpression TOP10F’ E. coli strain (see Appendix C for genotypes).
3.3.5 Isolate each plasmid construct and verify the gene sequences
using dideoxy sequencing. Once verified, batch purify plasmid
construct for stocks.
3.3.6 Digest pCR2.1-LcrV, pCR2.1-YscF, and pET24a+ plasmids and
isolate fragments for ligation.
3.3.7 Ligate gel-isolated LcrV and YscF DNA gene fragments into the
pET24a+ plasmid.
3.3.8 Transform plasmids into the non-selective, non-expression E. coli
strain DH5α and verify with restriction digestions.
33

3.3.9 Purify verified plasmid constructs and transform into E. coli
expression strain BL21(DE3).

Figure 15. Development of Expression Plasmids
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3.3.1 Design NdeI and XhoI primers for both LcrV and YscF coding
DNA from Y. pestis strain KIM5 as a target for PCR amplification
The DNA sequences from which LcrV (Table 3Table 3) and YscF (Table
4) proteins are encoded were taken from http://www.ncbi.nlm.nih.gov/.

The

sequences coding for both proteins are identical in both CO92 (virulent) and
KIM5 (avirulent) strains of Y. pestis. The LcrV coding DNA contains 981 bp
coding for a 37.2 kDal protein. The YscF coding DNA is much smaller, with 264
bp producing a 9.5 kDal protein.
Table 3. LcrV DNA Sequence
(Start and Stop Codons Underlined and Bolded)

atttaat
gag gat
tct tca
ata gat
ttt gcc
atc cta
cat tat
ttc ctt
atg gca
gat att
gcc cgt
tta aag
tct agt
atg gat
gcc agc
att cag
ttt ctt
aaa aac
ttt gcc
gtt agc
aat tca
tca gtg
cacgagg

atg
cta
gtt
att
aat
gct
gac
gaa
gta
ttg
agc
att
agt
aaa
gca
gtg
gga
tca
acc
caa
gct
atg

att
gaa
tta
tcc
aga
tat
aac
tca
atg
aaa
aag
tat
ggc
aat
gag
gat
agt
tac
acc
aaa
att
caa

aga
aaa
gaa
att
gta
ttt
caa
tcg
cat
gtg
ttg
tca
acc
tta
tac
ggg
gag
tct
tgc
aca
gaa
cgt

gcc
gtt
gaa
aaa
att
cta
ctg
ccg
ttc
att
cgt
gtt
ata
tat
aaa
agc
aat
tat
tcg
act
gca
ctg

tac
agg
ttg
tat
act
ccc
caa
aat
tct
gtt
gaa
att
aat
ggt
att
gag
aaa
aat
gat
cag
ctg
cta

gaa
gtg
gtt
gat
gat
gag
aat
aca
tta
gat
gaa
caa
atc
tat
ctc
aaa
aga
aaa
aag
ctg
aac
gat
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caa
gaa
cag
ccc
gat
gat
ggc
caa
acc
tca
tta
gcc
cat
aca
gag
aaa
acc
gat
tcc
tct
cgt
gac

aac
caa
tta
aga
atc
gcc
atc
tgg
gcc
atg
gct
gaa
gat
gat
aaa
ata
ggg
aat
agg
gat
ttc
acg

cca
ctt
gtc
aaa
gaa
att
aag
gaa
gat
aat
gag
att
aaa
gaa
atg
gtc
gcg
aat
ccg
att
att
tct

caa
act
aaa
gat
ttg
ctt
cga
ttg
cgt
cat
ctt
aat
tcc
gag
cct
tcg
ttg
gaa
ctc
aca
cag
ggt

cat
ggt
gat
tcg
ctc
aaa
gta
cgg
atc
cat
acc
aag
att
att
caa
ata
ggt
tta
aac
tca
aaa
aaa

ttt
cat
aaa
gag
aag
ggc
aaa
gcg
gat
ggt
gcc
cat
aat
ttt
acc
aag
aat
tct
gac
cgt
tat
tga

att
ggt
aat
gtt
aaa
ggt
gag
ttc
gat
gat
gaa
ctg
ctc
aaa
acc
gac
ctg
cac
ttg
ttt
gat

Table 4. YscF DNA Sequence
(Start and Stop Codons Underlined and Bolded)

atc
gac
gat
att
cgt
taa

aaaataa
gca gac
gat gca
aag cct
aat aaa
agc atg
tatgaaa

atg
tta
aac
gac
tgg
aaa

agt
gat
aaa
aac
tcg
gac

aac
gcg
gcg
ccg
gta
tta

ttc
gtg
gtt
gcg
att
atg

tct
gct
aat
cta
tac
caa

gga
caa
gac
ctt
aat
ggc

ttt
acg
tcg
gct
ata
atc

acg
ctc
ata
gac
aac
cta

aaa
aag
gca
tta
tca
cag

gga
aag
gca
caa
acc
aag

acc
cca
ttg
cat
ata
ttc

gat
gca
aaa
tca
gtt
cca

The pET24a+ vector (Appendix D. pET24a+ Vector Map) is designed to
enhance expression driven by production of mRNA using T7 RNA polymerase
targeting the T7 promoter (T7P) upstream of the inserted DNA sequence.
Expression is controlled by lacUV5 promoter and operator regions. The operator
region is normally bound with the repressor protein blocking transcription.
Lactose or an analogue such as isopropyl-β-D-thio-galactoside (IPTG), bind to
the repressor, releasing operation region, greatly increasing transcriptional
expression. For ligation with correct orientation (T7P 5’ of translated sequence)
in the pET24a+ expression vector the primer sets were designed with NdeI and
XhoI 3’ overhangs.

The restriction enzyme NdeI selectively digests (cleaves

DNA backbone) the DNA recognition sequence CATATG. This sequence is cut
asymmetrically, leaving an overhang (Figure 16).

Figure 16. NdeI Restriction Enzyme Leaving 3’ Overhang
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Since the start codon common to most living organism is ATG, the NdeI
restriction site is easily constructed by adding CAT (the complimentary three
bases) upstream to the start codon. The complimentary strand’s primer was
tagged with an XhoI site (C/TCGAG). The final primer design for amplification of
LcrV and YscF DNA amplicons are presented below in Table 5.
Table 5. LcrV and YscF Primers

Forward
Primer
Reverse
Primer
Forward
Primer
Reverse
Primer

LcrV

YscF

LcrVNde-I

5'-TAGCATATGATTAGAGCCTACGAAC-3'

LcrVXho-I

5'-CTCGAGTCATTTACCAGACGTGTC-3'

YscFNde-I

5'-TAGCATATGAGTAACTTCTCTGG-3'

YscFXho-I

5'-CTCGAGTTATGGGAACTTCTGTAG-3'

3.3.2 Develop PCR amplification protocols for creating NdeI/XhoI
sites 5’ and 3’, respectively, to the LcrV and YscF coding PCR product from
Y. pestis KIM5 genomic DNA
The

commercially

synthesized

primers

were

resuspended

with

DNAse/RNAse Free PCR grade water; and aliquots of the resuspended primers
were diluted to a concentration of 1 ug/uL with water. The KIM5 genomic DNA
was diluted to 3 ng/uL prior to amplification. AccuPrime™ Taq DNA Polymerase
(Invitrogen™) and 10x buffer II were selected based on ease of use and
sufficient amplification fidelity. The reaction volume (30 uL):
•
•
•
•
•
•

3 uL 10x PCR Buffer II (includes MgCl2 and dNTPs)
0.5 uL AccuPrime™ Taq Polymerase
3 uL (0.1 ug/uL) forward primer (LcrVNde-I or YscFNde-I)
3 uL (0.1 ug/uL) reverse primer (LcrVXho-I or YscFXho-I)
19.5 uL DNAse/RNAse Free PCR grade water
1 uL (3 ng/uL) purified Genomic KIM5 DNA
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The PCR thermocycling conditions differed for LcrV and YscF due to the
lengths of amplicons. The longer the amplified region the longer the time needed
during the elongation stage (secondary cycles).

The PCR reactions were

separated into two stages: an initial ten cycles were performed using less
restrictive parameters (lower annealing temperatures and longer elongation
time), followed by 25 cycles at more stringent hybridization parameters (Table 6).
Table 6. PCR Conditions

LcrV
Stage

Quantity

Initial Denaturation

Primary Cycles

Secondary Cycles

Final Hold

1

10

25

1

YscF
Temp
(°C)

Time
(sec)

Stage

Quantity

Temp (°C)

Time (sec)

1

94

90

94

60

55

60

94

90

94

60

55

60

72

80

72

45

94

60

94

30

60

45

62

30

72

60

72

45

4

variable

4

variable

Initial Denaturation

Primary Cycles

Secondary Cycles

Final Hold

10

25

1

The above reactions were run in duplicate with negative controls (water in
place of template DNA). The reactions were run on 0.75% agarose gels with
ethidium bromide staining. The appropriate bands (LcrV ~985 bp and YscF ~270
bp) were identified, excised, and isolated using a DNA Extraction Kit (QIAGEN™)
according to the manufacturer’s suggested protocol. The purified DNA fragments
were stored at -20°C prior to ligation.
3.3.3 Ligate the LcrV and YscF PCR products into pCR2.1 vector
plasmids
As an artifact of Taq polymerase activity, adenine bases are usually added
to the 3’ ends of the amplicons. The pCR2.1 vector supplied by Invitrogen™ is
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provided linearized with 3’ thymine overhang ends, which take advantage of this
inherent property of Taq polymerase by providing a nonspecific overhang for any
PCR product.

These adenine and thymine overhang ends hybridize, covalently

joining the pCR2.1 vector with the isolated PCR DNA fragments. Ligation was
completed using “The Original TA Cloning Kit” by Invitrogen™". The ligation
reactions (see below) totaling 15 uL were incubated at 14°C for 26 hours. The
resultant constructs ligating the pCR2.1 vector with either LcrV and YscF were
named pCR2.1-LcrV and pCR2.1-YscF, respectively.
Ligation Mix
•
•
•
•
•

0.5 uL (0.025 ug/uL) pCR2.1 vector
1.5 uL 10x ligation buffer
6 uL Water
1 uL T4 DNA ligase
6 uL purified PCR product

3.3.4 Transform pCR2.1-LcrV and pCR2.1-YscF vectors into the nonexpression TOP10F’ E. coli strain
The E. coli strain TOP10F’ (see Appendix C. Strains for genotype) was
selected due to its very low background expression of the protein in the
expression vector in the absence of inducing conditions. The constructs pCR2.1LcrV and pCR2.1-YscF were transformed into One Shot™ TOP10F’ chemically
competent cells (Invitrogen™). Once the purified plasmid was placed into cold
competent cells, the mixture was incubated on ice for 30 min then heat shocked
at 42°C 30 s.

To both cultures, 250 uL of room temperature S.O.C. media

(Invitrogen™) was added, and then incubated in a shaking incubator for 1 hr at
37°C at 225 RPM. 10 and 100 uL aliquots of the transformation solution were
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plated on S-Gal/KAN/LB agarose (Sigma-Aldrich Co.©) and incubated at 37°C
overnight. White colonies, representing clones with inserts, were picked and
used to inoculate 3 mL LB broth [50 ug/mL KAN] at 37°C at 225 RPM overnight.
3.3.5 Isolate each plasmid construct and verify the gene sequences
using dideoxy sequencing
The inoculates (1 mL) were spun (12.5 RCF, 5 min) and the DNA purified
from the cell pellet using S.N.A.P. mini prep kit (Invitrogen™) according to the
manufacturer instructions. The purified plasmid containing the gene inserts were
double digested with NdeI and XhoI restriction enzymes overnight.
Purified LcrV-pCR2.1 and YscF-pCR2.1 vectors (200 ng) were sent to the
Ohio State University’s Plant Microbe Genome Facility in Columbus, OH for DNA
sequencing to verify the fidelity of the amplification, ligation, and transformation.
By pair-wise alignment analysis, the two vector inserts were identified as
containing the correct LcrV and YscF DNA sequences without any mutations.
Unreadable base calls were analyzed using the software package ABI
Sequencing Analysis 5.2 Patch 2.

40

Figure 17. Sequencing Chromatographs

In order to ensure sufficient plamid for further manipulations, two 1 L
flasks containing 250 mL of LB broth [50 ug/mL kanamycin (KAN)] were
inoculated with 1 mL of the verified LcrV/YscF-pCR2.1 inoculums. These were
grown overnight at 37°C at 225 RPM and harvested by centrifugation with a
Sorvall RC-5B Refrigerated Superspeed Centrifuge at 6000 g for 15 min at 4°C in
a SLA-3000 rotor. The pellets were purified with QIAGEN Endofree Plasmid
Maxi Kits according to the manufacturer’s directions. The preps produced 1.2 ug
and 1.7 ug high purity pCR2.1-LcrV and pCR2.1-YscF plasmids, respectively,
which were stored at -20°C.
3.3.6 Digest pCR2.1-LcrV, pCR2.1-YscF, and pET24a+ plasmids and
isolate fragments for ligation
The screening vector pCR2.1 is not designed as an expression vector and
thus is not used for large scale protein production. After sequence verification
and large scale production, pCR2.1-LcrV, pCR2.1-YscF, and pET24a+ vector
were digested with the restriction enzymes NdeI and XhoI.
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The LcrV gene

sequence contained a naturally occurring XhoI site (CTCGAG italicized in Table
3), which could fragment the gene into two pieces upon XhoI digestion.
Fortunately, neither XhoI restriction site was preferentially cut, and, a partial XhoI
digestion was conducted by stopping the digest after 1-hr. Sufficient full size
product could be recovered at this point (Figure 18). The LcrV and YscF DNA
containing bands, as well as the linearized pET24a+ vector, were separated by
agarose gel and the DNA fragments isolated using DNA Extraction Kit
(QIAGEN™) according to the manufacturer’s suggested protocol. The purified
DNA was stored at -20°C prior to ligation.

Figure 18. Depiction of Plasmid Switching
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3.3.7 Ligate gel-isolated LcrV and YscF DNA gene fragments into the
pET24a+ plasmid
Following digestion and purification of the expression vector components
(LcrV, YscF, and linearized pET24a+ vector), the complementary overhang ends
were ligated. The ligation reactions (see below) totaling 20 uL were incubated at
23°C for 4 hours and stored at -20°C until transformation.
Ligation Reaction
•
•
•
•
•

4 uL linearized pET24a+ (~10-ng/uL)
8 uL purified LcrV digest product or 5 uL YscF digest product
4 uL 5x ligation buffer
1 uL water (LcrV) or 4 uL water (YscF)
3 uL T4 DNA ligase diluted 1/10

3.3.8 Transform plasmids into the non-selective, non-expression E.
coli strain DH5α and verify with restriction digestions
Ideally, the expression vector pET24a+ vector will not express (produce
transcripts) the protein encoded in the vector; however, low level background
transcription often does occur from minor promoter/operator regions in noninducive conditions, producing very small quantities of protein.

The energy

required for protein production or the toxicity of the protein lowers the cell’s
reproductive rate thus negatively affecting the cell’s competitiveness within a
heterogeneous culture.

If this occurs, this effect selects against the cells

containing the correct gene insert.

DH5α (Appendix C. Strains) does not

promote this background expression and also carries the recA1 and endA1
mutations which help stabilize the plasmids and increase plasmid isolation yields.
The same protocol from section 3.3.4 was used for this transformation and
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culture. Blue/White screening capability have not been constructed within the
pET24a+ vector; therefore, additional screening was necessary.
3.3.9 Purify verified plasmid constructs and transform into E. coli
expression strain BL21(DE3)
The E. coli strain BL21(DE3) was selected as it is able to overexpress the
transcripts, thus the proteins, using the T7 RNA promoter induced by the
synthetic lactose analog, IPTG. The expression vector containing the LcrV and
YscF genes were purified from the DH5α isolated constructs (similar to protocols
sections 3.3.5 and 3.3.8) and transformed into Novagen Bl21(DE3) Chemical
Competent Singles™ as in section 3.3.4. Colonies were picked and selected
using restriction digestion.
3.4 Expression of recombinant LcrV and YscF proteins
3.4.1 Overview
With the expression vectors constructed and verified, the next step was to
express recombinant LcrV and YscF. The process of producing the protein was
broken into three tasks. First, small test protein expressions were conducted to
verify for the correct protein size. Second, large scale test expressions were
conducted and the protein gel isolated and sequenced to verify the correct amino
acid sequence.

Lastly, if insufficient expression was observed, conduct

growth/induction optimization tests and repeat task two. Figure 19 represents
the steps used in expressing LcrV and YscF. The optimized LcrV and YscF
cultures were lysed and the cellular debris pelleted by centrifugation. The LcrV
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expression did not require optimization, whereas YscF did require additional
testing.

Figure 19. Protein Expression Overview

3.4.2 Protein Test Expressions
In the previous section 3.3 the methods for plasmid construction was
described. For test expressions, five colonies for both pET-LcrV and pET-YscF
were picked and tested in parallel. A loop of ~10 uL overnight saturated culture
was used to inoculate 3 mL of LB broth [50 ug/mL KAN]. The culture was grown
to an OD600 ~0.5 before induction with IPTG [0.1 M]. After induction, the cultures
were allowed to grow at 37ºC overnight. The cultures were then spun at 10K
RCF for 10 minutes, resuspended in SDS loading dye, and visualized by
electrophoresis with Coomassie staining.
The construct which produced the highest level of protein was selected for
each LcrV and YscF. The protein products for both LcrV and YscF constructs
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were submitted for analysis using liquid chromatography coupled with mass
spectroscopy (LC/MS) of tryptic peptides.
3.4.3 Large Scale Production
In order to produce sufficient protein the production was scaled up ~1000
fold from 3 mL to 2 L. For LcrV, a 100 mL overnight seed culture grown to
maximal density was transferred en masse into 4 L Erlenmeyer flask with 2 L LB
broth [50 ug/mL KAN]. The culture was grown to OD600 ~0.5, induced with 0.1 M
IPTG, and incubated overnight at 37°C at 225 RPM.
In order to express the protein YscF in BL21(DE3), smaller volume
Erlenmeyer flasks with baffles were required. The 2 L volume was split between
eight 1 L baffled flasks containing 250 mL of LB with KAN. The large production
cultures were grown to OD600 ~1.2, induced with 0.1 M IPTG, and incubated
overnight at 37°C at 225 RPM.
3.4.4 Harvesting
The cells were harvested by centrifugation with a Sorvall RC-5B
Refrigerated Superspeed Centrifuge and SLA-3000 Fixed Angle Rotor at 6K g for
15 min at 4°C. The supernatant was removed and the pellet was resuspended
with 6 mL of 20 mM PB (pH 6.6) per gram of cells with 1 mL of 10x protease
inhibitor cocktail added to limit proteolytic degradation. The cell slurry mix was
kept on ice for the entire resuspension process. Following resuspension the cell
slurry was lysed by two passes through a Thermo Electron French Press Cell
Disrupter and a 40K French Pressure Cell. The YscF cell resuspension mix, in
addition to the protease inhibitor, contained 1% Triton and 100 ug/250 mL
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lysozyme. The lysed cell slurries were then centrifuged at 15K x g 20 min at 4°C
to pellet cellular debris. The supernatant was removed and stored at -20°C.
3.5 Protein Purifications
3.5.1 Overview
Due to physical differences (size, hydrophobicity, and solubility),
purification of LcrV and YscF required different protein purification procedures.
The primary instrument used in purification was an Amersham Biosciences
AKTAexplorer Fast Protein Liquid Chromatography (FPLC). FPLC is very similar
to high performance liquid chromatography (HPLC) but the FPLC columns
tolerate larger quantities of crude protein extract at lower pressures without
clogging the column or overpressure damage. Columns of varying properties
were employed in series to achieve the final LcrV and YscF purity levels.
3.5.2 LcrV Protein Purification Protocol
3.5.2.1 Ammonium Sulfate Precipitation
A quick, cheap, and simple method for removing many unwanted proteins
is precipitation using ammonium sulfate (ASP). Ammonium sulfate is a highly
soluble salt which effectively dehydrates the area surrounding the proteins in
solution. As the proteins become less soluble they precipitate out of solution and
are easily removed via centrifugation.
The LcrV pellet from 3.4.4 was resuspended in 50mM phosphate, 150mM
NaCl (pH 7.2 buffer). Several ammonium sulfate precipitations, or “cuts,” were
made by progressively adding quantities of ammonium sulfate salt to the LcrV
solution. After each cut the solution was spun down, and the precipitate and
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supernatant was analyzed for LcrV. The 1.5 M ammonium sulfate fraction (tube
2 in Figure 20) precipitated most of the unwanted proteins leaving LcrV in
solution.

Figure 20. Test Ammonium Sulfate Precipitation Overview

3.5.2.2 FPLC Purification Step 1
The 1.5 M ammonium sulfate solution containing LcrV was loaded onto a
Source 15PHE 4.6/100 PE column using a protocol established by Mr. Jordan
Williamson with conditions described in Appendix A. The column fractions were
stored on ice, pooled, and concentrated using a 10 kDal spin column
concentrator.
3.5.2.3 FPLC Purification Step 2
The pooled and concentrated LcrV solution was loaded onto a HiTrap
column to exchange it from high salt buffer (50 mM sodium phosphate and
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residual ammonium sulfate, pH 7.2) to a lower salt buffer (20 mM Tris, pH 8).
The lower salt LcrV solution was further purified using a MiniQ ion-exchange
column from GE Healthcare Life Sciences using the method in Appendix B.
Fractions 12-14 and 16-18 were pooled (most likely different quaternary
structures of LcrV). This pooled sample was treated with 100 ug of lysozyme per
250 mL total solution for 5 min. The precipitant was pelleted and the supernatant
was passed though a size exclusion column to yield the final solution containing
~99% purified LcrV.
3.5.3 YscF Protein Purification Protocol
3.5.3.1 Ammonium Sulfate Precipitation
A 20% ammonium sulfate concentration with lysozyme precipitated YscF
from solution. The pelleted YscF precipitate was used for further purification,
unlike LcrV, which used the fraction that remained in solution. YscF (9.5 kDal) is
a relatively small protein and to remove higher molecular weight contaminants,
the pellet was twice washed with 20 mM Tris, 1% (v/v) Triton X-100, 150 mM
NaCl (pH 8), as we have seen that YscF is not soluble in NaCl solutions. After
washings, the YscF containing pellet was resuspended in 20 mM Tris, 0.05%
(v/v) Tween 20 (pH 8).
3.5.3.2 FPLC Purification
The resolubilized YscF solution was loaded onto a size exclusion column
yielding the final solution containing purified YscF.
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4. Results and Discussion
4.1 Overview
Much of the early LcrV and YscF cloning steps were conducted in parallel
whereas the expression and purification steps were conducted separately. The
results of the LcrV and YscF production will be described separately.
4.2 LcrV
Figure 21 depicts each of the steps required to build an LcrV recombinant
protein producing construct from amplification of genomic Y. pestis DNA. Lanes
C and D from Figure 21 are from the amplification of genomic Y. pestis KIM5 and
CO92 DNA, respectively. CO92 DNA was not used for the building the construct;
however, sequences are completely homologous.

Figure 21. LcrV DNA

The KIM5 DNA amplicon from lane C was ligated to pCR2.1 vector,
transformed into TOP10F’, and plated onto LB agar plates with KAN. When the
pCR2.1 vector is transformed into TOP10F’ without the insertion of a piece of
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DNA, the enzyme β-galactosidase is produced. β-galactosidase metabolizes Sgal® (a modified galactose sugar) producing an insoluble blue product.
Therefore, white colonies (Figure 22) have a DNA sequence inserted in the
pCR2.1 plasmid disrupting the βgal gene sequence and preventing the S-gal®
metabolism.

Figure 22. Blue/White Transformation Screening

Several clones were selected, plasmid DNA isolated, digested with the
restriction enzymes NdeI and XhoI and the fragments analyzed via agarose gel.
This step screened out plasmid inserts that were not the correct size as predicted
by published LcrV DNA sequence. Lanes E (NdeI) and F (NdeI and XhoI) are
pCR2.1-LcrV digests. The LcrV DNA bands in lanes F and H are cut with XhoI
(CTCGAG) twice, as there is an additional XhoI site internal to the sequence
(Table 3).

The colonies with correctly sized inserts (not shown) were DNA

sequenced using the primers T7P and R which hybridize just 5’ and 3’ to the
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insert sequence. Using this vector, the PCR fragment is not directionally aligned
into the vector.

Sequencing of both 5’ and 3’ directions aids in obtaining

complete sequence from long inserts, as DNA sequences by standard methods
often become less reliable after 1000 bp. Also, difficult regions to sequence,
such as repeat strings of >6 nucleotides, are often miscalled by the software that
translates the chromatogram to a sequence. The sequence from colony 1 is
given in Appendix G.
The pCR2.1-LcrV vector was digested, the DNA insert ligated into the
expression vector pET24a+, and the construct transformed into the nonexpression strain DH5α. The following picture is an example of a successful
transformation into E. coli.

Figure 23. Transformation Plate

The correct insertion of the LcrV DNA into pET24a+ was initially screened
with NdeI/XhoI digest and analyzed with gel electrophresis. Figure 21 lane G is
the singly cut (NdeI) and Lane H is the double cut construct. pET24a+-LcrV was
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tranformed into BL21(DE3), colonies picked, and test expressions were
conducted to screen the colony producting the highest levels of LcrV. Figure 25
(D induced) has a band that is much larger then the uninduced control lane. The
predicted size of LcrV (37.24 kDal) was predicted using ExPASy, a protein
identification and analysis software set available at (http://ca.expasy.org/). The
protein from the test inductions ran at 35 kDal (Figure 24).

Following the

successful induction, the constructs were archived in 15% glycerol and stored at
-80ºC. This allows for future production of the protein without transformation.
The vector map for pET24a+-LcrV is depicted in Appendix H.

Figure 24. LcrV and YscF Test Expressions

The identity of the band was further confirmed by protein sequencing
using LC/MS by the proteomics facility in the Applied Biotechnology Branch of
the Air Force Reseach Laboratory run by Dr. Pavel Shiyanov. The results can be
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seen in Appendices E and F. The N-terminal methionine on both LcrV and YscF
were not detected, resulting in 99% and 98% coverage to the predicted
sequences, respectively. This 1-2% difference is due to methionine processing
which occurs in the cytoplasm of E. coli by methionine aminopeptidase (MAP or
ampM) (Gellissen 2005).

This results in the cleavage of the N-terminal

methionine residue and accounts for the less than perfect homology.

The

enzyme MAP is also produced by Yersinia species; therefore the post
translational cleavage of N-terminal methionines by produced E. coli does not
significantly alter the recombinant protein from its native form (NCBI 2009).
Large scale growth of recombinant LcrV was easily upscaled from 2 mL to
2 L without modifying the procedure. Cell lysis (in conjunction with Mr. Jordan
Williamson and Dr. David Riddle) was greatly aided by the addition of lysozyme,
which cleaves 1,4-beta-linkages in E. coli’s cell wall.

These cell wall

constituents, if untreated, may stick to isolated proteins and hinder purification.
Figure 27 (Appendix B) would be much purer had lysozyme treatment been
used, as with YscF, before purification with the FPLC.
The series of FPLC purification steps performed by Riddle and Williamson
resulted in a product of 99% purity.
4.3 YscF
Figure 25 depicts each of the steps required to build an YscF recombinant
protein producing construct from amplification of genomic Y. pestis DNA. Figure
25 lanes C and D show the amplification of genomic Y. pestis KIM5 and CO92
DNA, respectively.
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Figure 25. YscF DNA

The same process was used for YscF as was described in 4.2. The lanes
represent (A) Ladder, (B) Negative Control, (C) YscF DNA from KIM5 Genomic,
(D) YscF DNA from CO92 (for reference only), (E) pCR2.1-YscF NdeI digest, (F)
pCR2.1-YscF NdeI/XhoI digest, (G) pET24a+-YscF NdeI digest, and (H)
pET24a+-YscF NdeI/XhoI digest. The sequence for pCR2.1-YscF using the T7P
primer is given in Appendix G. The vector map for pET24a+-YscF is depicted in
Appendix I. A whole cell crude protein sample from the 3 mL test induction was
run on a SDS-PAGE gel with Coomassie staining (Figure 24).

The colony

producing the highest level of protein was archived in glycerol and stored at 80ºC.
Large scale production of recombinant YscF required using multiple flasks
of smaller volumes. Multiple attempts using a standard 4 L flask without baffles
with 2 L of culture did not produce a noticeable YscF band. Spitting the 2 L
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culture between eight 1 L flasks with baffles each with 250 mL of culture
produced a very noticeable band in the range of YscF’s predicted size. One
explanation is the YscF producing culture strictly requires high levels of
oxygenation. The large 2 L culture, grown in a smooth bottom flask, did not
produce a large froth compared to the flasks with baffles. Also, perhaps without
the baffles agitating the E. coli, a film could develop that repressed YscF
expression.
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5. Conclusions and Future Research Considerations
5.1 Overview
The production and purification of the two recombinant proteins LcrV and
YscF is an initial step and an important milestone in accomplishing VHH
production as described in the DTRA proposal titled “Use of Epitope-directed
Nanobodies® as Passive Immunotherapeutic Agents Against Yersinia pestis.”
Several choke points and setbacks had to be dealt with during this project.
Initially the E. coli strain NOVABLUE (Novagen) was used as the non-expression
host for pET24a+-LcrV and YscF.

After several transformation attempts, we

came to the assumption that perhaps even basal expression, albeit low, killed the
bacteria with the successful construct insert. The LcrV protein was suspected of
being cytotoxic as it was thought to be a transmembrane protein with both
hydrophobic and hydrophilic moieties.
protein

sequence

analysis

software

However, upon closer analysis with
(http://ca.expasy.org/tools/protparam-

doc.html), the primary structure is largely charged with 52 positively and 43
negatively charge amino acids. LcrV’s total average hydropathicity score was
found to be -0.549 (charge amino acids are given negative values and uncharged
positive). Since we believed the protein to be toxic we decided to try another
non-expression E. coli strain DH5α. After multiple attempts with a two different
lots of DH5α, the construct was successfully transformed. The LcrV purification
was relatively straight forward.

The protein stayed in solution during

concentration and purification.

57

YscF, after production and during purification, indicated a high propensity
to self-aggregation. The aggregation caused the small protein to behave like a
much larger protein making purification and recovery difficult and unpredictable.
Unsuccessfully, several detergents added to the YscF precipitant to resolubilize
the protein. The process was unnecessary due to the discovery of the solubility
properties of YscF in high and low salt (NaCl) conditions. YscF even in low
concentrations self-agglomerates in even low salt conditions; however, it stays in
solution and can be easily purified if salt-free buffers are used. This finding is not
surprising as YscF is a small protein that forms needles by agglomeration. While
significant effort was put into developing and optimizing the purification protocols,
the entire process is evidence that fusion tags are not necessary for production
of recombinant proteins. The proteins produced as described in section 5 using
the methods from section 4 were shipped to AF collaborator Dr. Serge
Muyldermans (University of Belgium) for VHH production.
5.2 Continuation of Research
The proteins produced will be used as antigens in the Camelidae species
L. glama to produce a natural immune response leading to the production in the
host of antibodies and VHH. Post-injection blood will be drawn and the peripheral
blood lymphocytes isolated.

cDNA will be produced from lymphocyte mRNA

coding for the VHH domains from the Camelid antibodies, and these will be used
as a phage display to screen for the highest binding affinity to the protein
antigens used. Once panning is completed, the final DNA sequence coding for
the peptide with the highest binding affinity will be ligated into a vector and
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transformed into a bacterial cell line to produce unlimited supplies of the LcrV
and YscF VHH.
The developed LcrV and YscF VHH will be tested using an in vitro model
for the attenuation of infection using the avirulent Y. pestis KIM5 strain in human
primary macrophage cells. Following characterization in the in vitro model, the
VHH immunotherapeutic will be tested in an in vivo murine model for efficacy
against Y. pestis KIM5 exposure. In addition, the use of multiple VHH injections
will be examined to see if the period of protection can be extended and, if so, for
how long.
If VHH are successful in producing protection from Y. pestis post-exposure,
the immunotherapeutic will be tested in an in vivo model using a highly virulent Y.
pestis strain such as CO92.

If such data supports the use of Y. pestis

immunothepeutics, development of VHH to other agents (Botulinum toxin, F.
tularensis, etc.) will proceed, with hopes of developing a VHH “cocktail” capable of
providing a period of protection post-exposure, which will allow for the completion
of mission requirements in the event of a BW attack.
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Appendix A. LcrV Protein Purification with Source 15PHE 4.6/100 PE
Starting Buffer: 50 mM phosphate, 1.5 M ammonium sulfate, pH 7.0
Elution Buffer: 50 mM phosphate, pH 7.0
Flow Rate: 1.0 mL/min
Buffer Gradient:
Step 1: 0% elution buffer for 10 min
Step 2: 70% elution buffer for 15 min
Step 3: 80 % elution buffer for 10 min
Step 4: 100% elution buffer for 15 min
Sample Volume: 500 uL
The LcrV eluted out at approximately fraction 21 as shown in

Figure 26.
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Appendix B. LcrV Protein Purification with MiniQ 4.6/50 PE
Starting Buffer: 50 mM phosphate, 1.5 M ammonium sulfate, pH 7.0
Elution Buffer (B): 1 M NaCl, 20 mM Tris, pH 8
Flow Rate: 0.5 mL/min
Buffer Gradient: 0 to 40% Elution Buffer for 24 minutes
The LcrV eluted out at fractions 12-14 and 16-18 as shown in Figure 27.
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Figure 27. Output from FPLC for LcrV MiniQ
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Appendix C. Strains
E. coli Strains (in order of use)
q
R
TOP10F’ (Invitrogen™): F'[lacI Tn10(tet )] mcrA Δ(mrr-hsdRMS-mcrBC)
φ80lacZΔM15 ΔlacX74 deoR nupG recA1 araD139 Δ(ara-leu)7697
galU galK rpsL(StrR) endA1 λ-

DH5α (Invitrogen™): F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–
BL21(DE3) (Novagen™): F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI
lacUV5-T7 gene 1 ind1 sam7 nin5])

Y. pestis Strains (CO92 DNA for reference only)
KIM5 (Matt Niles at North Dakota): biovar Mediaevalis, pgm[DNA ONLY] CO92 (BEI Resourses): biovar Orientalis, isolated from a fatal
human case of primary pneumonic plague presumably contracted from an
infected cat, Colorado, U.S.A., 1992
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Appendix D. pET24a+ Vector Map

63

Appendix E. LcrV Protein Sequencing Results
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Appendix F. YscF Protein Sequencing Results
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Appendix G. LcrV and YscF 5’ DNA Sequencing Results

LcrV
>jr-YpL1T7P-T7P_039_B09.ab1
NNNNGNNNNNNCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTAGCATATGAT
TAGAGCCTACGAACAAAACCCACAACATTTTATTGAGGATCTAGAAAAAGTTAGGGTGG
AACAACTTACTGGTCATGGTTCTTCAGTTTTAGAAGAATTGGTTCAGTTAGTCAAAGAT
AAAAATATAGATATTTCCATTAAATATGATCCCAGAAAAGATTCGGAGGTTTTTGCCAA
TAGAGTAATTACTGATGATATCGAATTGCTCAAGAAAATCCTAGCTTATTTTCTACCCG
AGGATGCCATTCTTAAAGGCGGTCATTATGACAACCAACTGCAAAATGGCATCAAGCGA
GTAAAAGAGTTCCTTGAATCATCGCCGAATACACAATGGGAATTGCGGGCGTTCATGGC
AGTAATGCATTTCTCTTTAACCGCCGATCGTATCGATGATGATATTTTGAAAGTGATTG
TTGATTCAATGAATCATCATGGTGATGCCCGTAGCAAGTTGCGTGAAGAATTAGCTGAG
CTTACCGCCGAATTAAAGATTTATTCAGTTATTCAAGCCGAAATTAATAAGCATCTGTC
TAGTAGTGGCACCATAAATATCCATGATAAATCCATTAATCTCATGGATAAAAATTTAT
ATGGTTATACAGATGAAGAGATTTTTAAAGCCAGCGCAGAGTACAAAATTCTCGAGAAA
ATGCCTCAAACCACCATTCAGGTGGATGGGAGCGAGAAAAAAATAGTCTCGATAAAGGA
CTTTCTTGGAAGTGAGAATAAAAGAACCGGGGCGTTGGGTAATCTGAAAAACTCATACT
CTTATAATAAAGATAATAATGAATTATCTCACTTTGCCACCACCTGCTCGGATAAGTCC
AGGCCGCTCAACGACTTGGTTAGCCAAAAACAACTCAGCTGTCTGATATTACATCACGT
TTCAATTCAGCTATTGAAGCACTGAACCGTTTCATTCANAAATATGATTCAGTGATGCA
ACGTCTGCTAGATGACACGTCTGGTAAATGACTCGAG

YscF
>jr-YpY1T7P-T7P_037_D09.ab1
NNNNNNNNNNGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTTAGC
ATATGAGTAACTTCTCTGGATTTACGAAAGGAACCGATATCGCAGACTTAGATGCGGTG
GCTCAAACGCTCAAGAAGCCAGCAGACGATGCAAACAAAGCGGTTAATGACTCGATAGC
AGCATTGAAAGATAAGCCTGACAACCCGGCGCTACTTGCTGACTTACAACATTCAATTA
ATAAATGGTCGGTAATTTACAATATAAACTCAACCATAGTTCGTAGCATGAAAGACTTA
ATGCAAGGCATCCTACAGAAGTTCCCATAACTCGAG
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Appendix H. pET24a+-LcrV Construct
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Appendix I. pET24a+-YscF Construct
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